TXA Central
TXA Central is a resource for health professionals caring for patients with acute severe bleeding
Month: March 2021
WOMAN-2 Trial
The WOMAN-2 trial investigates Tranexamic Acid (TXA) for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo-controlled trial.
Details
Art for Maternal Health Awareness
Healthcare is a human-right. Sculpture artist, Moira Purver was commissioned by the WOMAN trial to create this spectacular bronze statue, appropriately titled WOMAN, that depicts a mother on her knees holding her new baby in her arms just after giving birth. Every year 14 million mothers develop severe bleeding after childbirth or postpartum haemorrhage (PPH)
Details
A CRASH-3 Trial Sub-Study Provides Evidence of TXA Benefit in TBI
This sub-study found that when patients with unreactive pupils at baseline were excluded, there was evidence that TXA prevents new haemorrhage (adjusted RR=0.80, 95% CI 0.66 to 0.98).
Details
World Day of Remembrance for Road Traffic Victims
Even though evidence on the benefits of TXA in trauma has been available for over a decade, most trauma victims are still not being treated with TXA soon enough, if at all.
Details
WOMAN-PharmacoTXA Trial
The WOMAN-PharmacoTXA trial is a randomised controlled trial to assess the pharmacokinetics and pharmacodynamics of intramuscular, intravenous, and oral administration of tranexamic acid in women giving birth by caesarean section
Details